Drug Action
Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate induced platelet activation and aggregation.
PDF page 244
Loading InternPractice…
Drug reference
Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate induced platelet activation and aggregation.
PDF page 244
In combination with aspirin for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor (e.g. clopidogrel, prasugrel, ticagrelor) prior to the PCI procedure and in whom oral therapy with a P2Y12 inhibitor is not suitable (under expert supervision) ▶INITIALLY BY INTRAVENOUS INJECTION ▶Adult: Initially 30 micrograms/kg, to be given as a bolus dose, followed immediately by (by intravenous infusion) 4 micrograms/kg/minute, start treatment before percutaneous coronary intervention and continue infusion for at least 2 hours or for the duration of intervention if longer; maximum duration of infusion 4 hours
PDF page 244
Active bleeding. history of stroke. history of transient ischaemic attack. patients at increased risk of bleeding (e.g. impaired haemostasis, irreversible coagulation disorders, major surgery or trauma, uncontrolled severe hypertension)
PDF pages 244, 245
Disease states associated with increased bleeding risk
PDF page 245
→Appendix 1: cangrelor
PDF page 245
▶Common or very common Dyspnoea. haemorrhage. skin reactions ▶Uncommon Cardiac tamponade. haemodynamic instability . renal impairment. retroperitoneal haemorrhage (including fatal cases) ▶Rare or very rare Anaemia. haematoma infection. intracranial haemorrhage. menorrhagia. skin neoplasm haemorrhage. stroke. thrombocytopenia. vascular pseudoaneurysm. wound haemorrhage
PDF page 245
Manufacturer advises avoid—toxicity in animal studies.
PDF page 245
Manufacturer advises potential risk to infant —no information available.
PDF page 245
Manufacturer advises caution in severe renal impairment—increased risk of bleeding.
PDF page 245
For intravenous bolus injection and intravenous infusion, reconstitute each 50 mg vial with 5 mL of water for injection and gently swirl, do not shake vigorously. Withdraw 5 mL of reconstituted solution, add to 250 mL of either Sodium Chloride 0.9% or Glucose 5% and mix thoroughly. The bolus injection and infusion should be administered from the infusion solution.
PDF page 245
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for injection ▶Kengrexal (Chiesi Ltd) Cangrelor (as Cangrelor tetrasodium) 50 mg Kengrexal 50mg powder for concentrate for solution for injection / infusion vials | 10 vial P £2,500.00 (Hospital only) ANTITHROMBOTIC DRUGS › GLYCOPROTEIN IIB/IIIA INHIBITORS
PDF page 245
Initially 30 micrograms/kg, to be given as a bolus
First-line fragment. Read the complete Indications and Dose section above.
PDF page 244